Biologics in the treatment of active Psoriatic arthritis in China: a network meta-analysis and cost-effectiveness analysis
Expert Review of Pharmacoeconomics & Outcomes Research · 2025
DOI: 10.1080/14737167.2025.2451740 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Expert Review of Pharmacoeconomics & Outcomes Research, 2025. Verfasst von Ouyang Xie und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China. Hauptthemen laut MEDLINE: Arthritis, Psoriatic, Biological Products, Antirheumatic Agents. Die Arbeit nennt 47 Literaturangaben. Gefördert von: The Fundamental Research Funds for the Central Universities of Central South University, Hunan Provincial Natural Science Foundation of China, China Primary Health Care Foundation.
Abstract (Originalsprache)
BACKGROUND: Biologics are recommended for use in patients with psoriatic arthritis (PsA) after the failure of conventional systemic disease-modifying anti-rheumatic drugs (csDMARDs). However, compared to csDMARDs, biologics are significantly more expensive. The aim of this study was to evaluate the cost-effectiveness of biologic treatments for active PsA patients who have failed treatment with csDMARDs, from the perspective of the Chinese healthcare system. RESEARCH DESIGN AND METHODS: A discrete event simulation model was constructed to estimate health and economic outcomes of patients. The seven biologics recommended by the Chinese psoriasis treatment guidelines were included in the evaluation. One-way and probabilistic sensitivity analysis were performed to ensure that our results were robust. RESULTS: Our results found that compared to the standard of care (SoC) and all other biologics strategies, secukinumab (SEC) had the highest quality-adjusted life years, and at a willingness-to-pay (WTP) threshold of US $38,161 per QALY, SEC was the most cost-effective option, with an incremental cost-effectiveness ratio of $14,968 per QALY. One-way sensitivity analysis and probabilistic sensitivity analysis confirmed the robust of this result. CONCLUSIONS: From the perspective of the Chinese healthcare system, biologics are estimated to be cost-effective compared to SoC. Among these, SEC is the most cost-effective option.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
- Institute of Clinical Pharmacy, Central South University, Changsha, Hunan, China.
- Department of Rheumatology and Immunology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
- Clinical Medical Research Center for Systemic Autoimmune Diseases in Hunan Province, Changsha, China.
ORCID-Profile: Xiaomin Wan
Förderung
- The Fundamental Research Funds for the Central Universities of Central South University
- Hunan Provincial Natural Science Foundation of China
- China Primary Health Care Foundation
- Hunan Province Innovation Platform and Talent Plan, Clinical Medical Research Center Project
Zitieren
APA
Xie, O., Wu, M., Li, A., Meng, K., Xiang, H., Tan, C., Peng, L., Ge, Y., & Wan, X. (2025). Biologics in the treatment of active Psoriatic arthritis in China: a network meta-analysis and cost-effectiveness analysis. Expert Review of Pharmacoeconomics & Outcomes Research. https://doi.org/10.1080/14737167.2025.2451740
Vancouver
Xie O, Wu M, Li A, Meng K, Xiang H, Tan C, et al. Biologics in the treatment of active Psoriatic arthritis in China: a network meta-analysis and cost-effectiveness analysis. Expert Review of Pharmacoeconomics & Outcomes Research. 2025. doi:10.1080/14737167.2025.2451740
BibTeX
@article{Xie2025,
author = {Xie, Ouyang and Wu, Meiyu and Li, Andong and Meng, Kehui and Xiang, Heng and Tan, Chongqing and Peng, Liubao and Ge, Yan and Wan, Xiaomin},
title = {Biologics in the treatment of active Psoriatic arthritis in China: a network meta-analysis and cost-effectiveness analysis},
journal = {Expert Review of Pharmacoeconomics & Outcomes Research},
year = {2025},
doi = {10.1080/14737167.2025.2451740}
}
EUVIMED